Rubinstein MM, Doria ER, Konner J, Lichtman S, et al. Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. Gynecol Oncol 2022;169:64-69.
PMID: 36512912